血必净联合乌司他汀治疗感染性休克患者的临床疗效观察

Observation on clinical efficacy of Xuebijing combined with ulinastatin for treatment of septic shock

目的观察血必净联合乌司他汀治疗感染性休克的临床疗效,为今后治疗感染性休克患者提供依据。方法选取2013年1月-2015年6月92例在医院诊治的感染性休克患者进行观察,并按照数字表法随机分为试验组与对照组各46例,对照组给予常规治疗,试验组在对照组的基础上加入血必净联合乌司他汀治疗,观察两组患者的治疗效果、治疗前后的PiCCO测量指数变化(CO、CI、SVR、EVLWI)与血浆脑型利钠肽(BNP)、降钙素原(PCT)以及IL-6浓度,同时观察两组患者的病情变化。结果试验组患者治疗前后的PiCCO测量指数变化,包括:心输出量(CO)、心排血指数(CI)、体循环阻力(SVR)、血管外肺水指数(EVLWI)及BNP、PCT、IL-6变化均显著优于对照组,两组间比较差异有统计学意义(P<0.05);试验组患者的治疗总有效率为93.5%;显著优于对照组的82.6%,两组间比较差异有统计学意义(P<0.05)。结论血必净联合乌司他汀治疗感染性休克具有较好的临床疗效,能够改善患者病情,提高患者生活质量。

OBJECTIVE To observe clinical efficacy of Xuebijing combined with ulinastatin for treatment of septic shock,so as to provide reference for the future treatment of patients with septic shock.METHODS Totally 92 cases of septic shock in the hospital during Jan.2013 to Jun.2015 were selected and were divided into the test group and the control group by numeration table,46 patients in each group.The control group received conventional treatment,the test group received Xuebijing combined with ulinastatin on the basis of the control group.The two groups of patients were observed for therapeutic effects,changes in PiCCO index measurements（CO,CI,SVR,EVLWI）and plasma sodium brain-type natriuretic peptide（BNP）,pro calcitonin（PCT）and IL-6concentrations,changes in disease conditions were also observed in the two groups of patients.RESULTS PiCCO index measurements（CO,CI,SVR,EVLWI）,BNP,PCT and IL-6in the test group were superior to those in the control group before and after the treatment,and the difference was significant（P〈0.05）.The total efficacy of treatment was 93.5%in the test group,significantly better than 82.6%in the control group（P〈0.05）.CONCLUSIONXuebijing combined with ulinastatin for treatment of septic shock has better clinical efficacy,which can improve the patient＇s condition and improve the quality of life of patients.